Pinealon: What the Evidence Actually Shows

Pinealon is a short synthetic peptide sold for cognitive and neuroprotective support, marketed as part of the same Russian "peptide bioregulator" research tradition as Epitalon, already covered in this site's own evidence review — but it is a chemically different molecule, studied for a different primary use, with its own separate, genuinely thinner published record. This article checks what a live search of that record actually shows for Pinealon specifically, rather than borrowing Epitalon's own evidence or the broader bioregulator class's marketing framing.

What it actually is, and how it differs from Epitalon

Pinealon is a synthetic tripeptide, Glu-Asp-Arg (abbreviated EDR), developed by the same St. Petersburg Institute of Bioregulation and Gerontology research group behind Epitalon — but it is a different sequence, a different length (three amino acids versus Epitalon's four), and marketed under a different primary claim: cognitive protection and neuroprotection, rather than telomere length and longevity. A foundational cell-culture paper from that lab describes Pinealon's proposed mechanism directly: it "demonstrates dose-dependent restriction of reactive oxygen species (ROS) accumulation" in cultured cerebellar granule cells, neutrophils, and pheochromocytoma cells, decreases necrotic cell death, and appears to "interact directly with the cell genome" at higher concentrations, beyond its antioxidant effect alone¹. That is a real, published mechanistic finding — in cultured cells, not in a living person.

The published literature, sized precisely

A live PubMed search for "Pinealon" returns 22 total indexed papers — a genuinely thin literature, roughly one-sixth the size of Epitalon's own 142-paper record, this site's other article on this same research tradition. A live author-field search for "Khavinson" combined with "Pinealon" returns 8 of those 22 papers, about 36% — less concentrated in one lab's own output than Epitalon's 63%, though the majority of the remaining papers still trace to the same originating institute or its close collaborators. That smaller, less single-source-concentrated literature is a real, if modest, point in Pinealon's favor compared to Epitalon's own record — and it comes with a real tradeoff worth naming directly: there is simply less of it to evaluate in the first place.

What the human evidence actually shows — real, and genuinely limited

Unlike KPV, which has zero human data of any kind, or Epitalon, whose entire human evidence base is one single uncontrolled 2002 case report, Pinealon has something in between: a small number of real, published human observational studies, each with real limitations this article states directly rather than smoothing over. A 2012 study followed workers on railway locomotive crews — an occupational population exposed to documented aging-accelerating job stressors — who took oral Pinealon capsules (100mcg, twice daily) for two weeks; the paper reports improved parameters of "biological age" and adaptation-reaction effectiveness². That is the single most concrete, specific real-world dosing protocol located for Pinealon in the human literature — and it is notable for what it confirms about the real route of administration: oral capsule, not an injection.

A separate 2012 study compared 150 professional long-haul truck drivers against 150 metal-craftsman controls, examining rates of borderline mental disorders tied to occupational stress. Pinealon is named specifically, in combination with a second bioregulator peptide (vezugen), as part of the intervention that "restore[d] the organism adaptive potential, improved psychoemotional indices, [and] intensified resistance to work stress³" — real, statistically reported findings (p<0.001-0.05), from a combined-product protocol that makes Pinealon's own isolated contribution impossible to separate out from the published abstract alone. A third study, in 32 patients aged 41 to 83 with chronic multi-system illness and organic brain syndrome in remission, reports Pinealon (alongside a second peptide, Vesugen) produced a "significant anabolic effect" and improved central-nervous-system indicators — but the same paper states plainly, in a direct within-study comparison worth reporting exactly as written, that "Vesugen has demonstrated more visible geroprophylactic effect than Pinealon⁴" in that same cohort. None of these three studies describes randomization or blinding in its own abstract; all three are small, open-label, occupational-health or geriatric observational studies from a single Russian gerontology journal, not registered controlled clinical trials.

The animal evidence, kept separate from the human record

Beyond the human studies above, Pinealon's animal literature adds real, if non-human, support for its proposed neuroprotective mechanism. A 2012 study found Pinealon protected the offspring of pregnant rats with experimentally induced hyperhomocysteinemia (a condition linked to impaired fetal brain development), improving spatial learning and reducing oxidative-stress markers and necrotic cell counts in cerebellar neurons of the offspring⁵. That is a real, positive animal finding, reported here as animal-only — it does not extend to a human pregnancy claim, and no study located for this article tested that question in a person.

The regulatory picture

Pinealon has never had an FDA-approved drug product. A live check of DailyMed's structured-product-label search returns zero results for "pinealon," and openFDA's Drugs@FDA and FAERS databases both return no matches at all. A live, full-text search of FDA's current 503A Bulks List and its companion significant-safety-risks page found no mention of "pinealon" in either document — unlike several other peptides in this corpus (Epitalon, GHRP-2, GHRP-6), Pinealon has not been formally nominated for FDA's compounding-substance review process, at least as far as either current document shows.

What this means if you're considering it

None of the 31 providers this site's own reviews cover sell Pinealon — this site's own identity-layer research confirms it is not tagged to any reviewed seller. The evidence picture here sits in a real, specific place among this site's Khavinson-lab bioregulator coverage: less concentrated in one lab's own output than Epitalon, with a real (if small, uncontrolled, and mostly combined-product) human observational record rather than Epitalon's single case report — but also a considerably smaller overall literature to draw from, and no study located for this article that isolated Pinealon's own effect from the other bioregulator peptides it was frequently studied alongside. The one clear, concrete real-world detail this research located — the actual dosing protocol used in the locomotive-crew study, 100mcg oral capsules twice daily — is also a genuinely different route than the lyophilized injectable vial most commonly sold under this name in the U.S. peptide-research market today. Our reconstitution calculator does the vial-to-syringe arithmetic on the numbers you enter for that injectable product; it cannot confirm a vial matches any of the oral-capsule protocols the published human studies above actually used. Readers researching the broader bioregulator tradition can find our Epitalon evidence review here, covering the more heavily studied — and more heavily single-lab-concentrated — sibling compound from the same research program.